Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
These data indicate TAS5315 has potential as a novel therapeutic for immunological diseases associated with aberrant Btk signalling, including RA and CSU. Further evaluation of TAS5315 is warranted.
Authors
- Tomoe Fujita (ORCID: https://orcid.org/0009-0004-3161-8134)
- Mika Maeda
- Hideki Amano (ORCID: https://orcid.org/0000-0003-0855-1889)
- Yuji Kumagai (ORCID: https://orcid.org/0000-0001-6304-8878)
- Akiko Yamamoto (ORCID: https://orcid.org/0009-0005-5142-473X)
Institutions
- Kitasato University Hospital (JP)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1002/bcp.70039
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25